Arnout Voet
Arnout Voet
Hoofddocent (associate professor) KU Leuven
Verified email at - Homepage
Cited by
Cited by
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication
F Christ, A Voet, A Marchand, S Nicolet, BA Desimmie, D Marchand, ...
Nature chemical biology 6 (6), 442-448, 2010
The Saccharomyces cerevisiae EHT1 and EEB1 genes encode novel enzymes with medium-chain fatty acid ethyl ester synthesis and hydrolysis capacity
SM Saerens, KJ Verstrepen, SD Van Laere, DFRTJM Voet, AR Van v P
J Biol Chem 281, 4446-4456, 2006
FraC nanopores with adjustable diameter identify the mass of opposite-charge peptides with 44 dalton resolution
G Huang, A Voet, G Maglia
Nature communications 10 (1), 835, 2019
Reconstruction of ancestral metabolic enzymes reveals molecular mechanisms underlying evolutionary innovation through gene duplication
K Voordeckers, CA Brown, K Vanneste, E van der Zande, A Voet, S Maere, ...
PLoS biology 10 (12), e1001446, 2012
Fragment based drug design: from experimental to computational approaches
A Kumar, A Voet, KYJ Zhang
Current medicinal chemistry 19 (30), 5128-5147, 2012
Identification of the LEDGF/p75 binding site in HIV-1 integrase
K Busschots, A Voet, M De Maeyer, JC Rain, S Emiliani, R Benarous, ...
Journal of molecular biology 365 (5), 1480-1492, 2007
Androgen receptor antagonists for prostate cancer therapy
C Helsen, T Van den Broeck, A Voet, S Prekovic, H Van Poppel, S Joniau, ...
Endocrine-related cancer 21 (4), T105-T118, 2014
Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV
A Hombrouck, J De Rijck, J Hendrix, L Vandekerckhove, A Voet, ...
PLoS pathogens 3 (3), e47, 2007
An integrated map of HIV genome-wide variation from a population perspective
G Li, S Piampongsant, NR Faria, A Voet, AC Pineda-Peña, R Khouri, ...
Retrovirology 12, 1-18, 2015
Pharmacophore modeling: advances, limitations, and current utility in drug discovery
X Qing, X Yin Lee, J De Raeymaeker, J RH Tame, K YJ Zhang, ...
Journal of Receptor, Ligand and Channel Research, 81-92, 2014
Computational design of a self-assembling symmetrical β-propeller protein
ARD Voet, H Noguchi, C Addy, D Simoncini, D Terada, S Unzai, SY Park, ...
Proceedings of the National Academy of Sciences 111 (42), 15102-15107, 2014
Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes
JE Neggers, B Kwanten, T Dierckx, H Noguchi, A Voet, L Bral, K Minner, ...
Nature Communications 9 (1), 502, 2018
Guards of the great wall: bacterial lysozyme inhibitors
L Callewaert, JM Van Herreweghe, L Vanderkelen, S Leysen, A Voet, ...
Trends in microbiology 20 (10), 501-510, 2012
The effect of F877L and T878A mutations on androgen receptor response to enzalutamide
S Prekovic, ME van Royen, ARD Voet, B Geverts, R Houtman, D Melchers, ...
Molecular cancer therapeutics 15 (7), 1702-1712, 2016
Functional conservation of HIV-1 Gag: implications for rational drug design
G Li, J Verheyen, SY Rhee, A Voet, AM Vandamme, K Theys
Retrovirology 10, 1-11, 2013
The transcriptional co-activator LEDGF/p75 displays a dynamic scan-and-lock mechanism for chromatin tethering
J Hendrix, R Gijsbers, J De Rijck, A Voet, J Hotta, M McNeely, J Hofkens, ...
Nucleic acids research 39 (4), 1310-1325, 2011
Duplication of a promiscuous transcription factor drives the emergence of a new regulatory network
K Pougach, A Voet, FA Kondrashov, K Voordeckers, JF Christiaens, ...
Nature Communications 5 (1), 4868, 2014
In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2
R Vancraenenbroeck, J De Raeymaecker, E Lobbestael, F Gao, ...
Frontiers in molecular neuroscience 7, 51, 2014
Biochemical and structural characterization of TLXI, the Triticum aestivum L. thaumatin-like xylanase inhibitor
E Fierens, K Gebruers, ARD Voet, M De Maeyer, CM Courtin, JA Delcour
Journal of Enzyme Inhibition and Medicinal Chemistry 24 (3), 646-654, 2009
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137
A Hombrouck, A Voet, B Van Remoortel, C Desadeleer, M De Maeyer, ...
Antimicrobial agents and chemotherapy 52 (6), 2069-2078, 2008
The system can't perform the operation now. Try again later.
Articles 1–20